Galera Therapeutics OM candidate gc4419 is the closest to b-om. Their phase 2b trials finished around the same time(galera 6/15/17 vs ipix 8/7/17), though galera enrolled 223 pts vs ipix 61. Both companies had results that were statically significant(will have to double check if it was for all or some endpoints).
They completed enrollment of respective 2b trials 54 days apart. Galera announced btd on 2/28/18(~8 months after 2b enrollment completion, they announced 150M in finacing on 9/19/18(~15 months after 2b enrollment completion), and dosing of the first patient in the phase 3 OM study on 10/23/18(~16 months after 2b patient enrollment).
ipix completed 2b patient enrollment 20.75 months ago.